Phosphatidylinositol 4-kinase is a viable target for the radical cure of Babesia microti infection in immunocompromised hosts

Shengwei Ji1, Eloiza May Galon1, Moaz M. Amer1,2, Iqra Zafar1, Masashi Yanagawa3, Masahito Asada1, Jinlin Zhou4, Mingming Liu5* and Xuenan Xuan1*

1National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido, Japan, 2Biotechnology Department, Animal Health Research Institute, Dokki, Egypt, 3Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido, Japan, 4Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China, 5School of Basic Medicine, Hubei University of Arts and Science, Xiangyang, China

Human babesiosis is a global emerging tick-borne disease caused by infection with intra-erythrocytic parasites of the genus Babesia. With the rise in human babesiosis cases, the discovery and development of new anti-Babesia drugs are essential. Phosphatidylinositol 4-kinase (PI4K) is a widely present eukaryotic enzyme that phosphorylates lipids to regulate intracellular signaling and trafficking. Previously, we have shown that MMV390048, an inhibitor of PI4K, showed potent inhibition against Babesia species, revealing PI4K as a druggable target for babesiosis. However, twice-administered, 7-day regimens failed to clear Babesia microti parasites from the immunocompromised host. Hence, in this study, we wanted to clarify whether targeting PI4K has the potential for the radical cure of babesiosis. In a B. microti-infected SCID mouse model, a 64-day-consecutive treatment with MMV390048 resulted in the clearance of parasites. Meanwhile, an atovaquone (ATO) resistant parasite line was isolated from the group treated with ATO plus azithromycin. A nonsynonymous variant in the Y272C of the cytochrome b gene was confirmed by sequencing. Likewise, MMV390048 showed potent inhibition against ATO-resistant parasites. These results provide evidence of PI4K as a viable drug target for the radical cure of babesiosis, which will contribute to designing new compounds that can eradicate parasites.

KEYWORDS
Babesia microti, babesiosis, phosphatidylinositol 4-kinase, treatment, MMV390048
Introduction

Human babesiosis is a tick-borne disease caused by several Babesia species, of which Babesia microti is one of the main agents (Vannier et al., 2015). B. microti infection shows a wide spectrum of symptoms from asymptomatic to fatal disease, particularly in immunocompromised or elderly patients (Vannier et al., 2015). Most cases occur in the United States (U.S.), especially in the northeastern and northern midwestern regions (Krause, 2019). For the time being, the treatment of human babesiosis, as recommended by Centers for Disease Control and Prevention (CDC), usually involves the combination of atovaquone (ATO) plus azithromycin (AZI) for 1-2 weeks, which exhibits fewer side effects compared to an alternative combined therapy of clindamycin and quinine (Vannier and Krause, 2012). The treatment period for babesiosis may extend to six weeks or more in severely immunocompromised patients, and cytochrome b (Cytb) and ribosomal protein subunit L4 (rpl4) mutations were associated with parasite resistance to ATO and AZI, respectively, resulting in treatment failure (Krause et al., 2008; Wormser et al., 2010; Vannier and Krause, 2012; Simon et al., 2017). Another recommended regimen for babesiosis, clindamycin combined with quinine, is frequently associated with side effects, such as hearing loss, vertigo, and tinnitus (Renard and Ben Mamoun, 2021). Due to limited options, this treatment is still recommended for patients with severe babesiosis (Renard and Ben Mamoun, 2021). Moreover, previous reports revealed that monotherapy with quinine, clindamycin, or AZI was ineffective against B. microti infection in immunocompromised hosts (Lawres et al., 2016). Therefore, the buildout of new drug candidates or targets is urgently needed for the control and treatment of human babesiosis. Phosphatidylinositol 4-kinase (PI4K) is a ubiquitous eukaryotic lipid kinase involved in the production of phosphatidylinositol 4-phosphate (PI4P) (Li et al., 2021). PI4K has been reported to play a key role in the occurrence and development of cancer, viral infections, and malaria (Li et al., 2021). PI4K not only exhibits the potential for eliminating malaria (McNamara et al., 2013; Paquet et al., 2017), but also possesses an inhibitory effect against Babesia species, as we recently reported (Ji et al., 2022). The 2-aminopyridine MMV390048, a representative of a new chemical class of Plasmodium PI4K inhibitor (Paquet et al., 2017), showed potent inhibition against B. gibsoni in vitro, and against B. rodhaini and B. microti in vivo (Ji et al., 2022). However, twice-administered, short-time treatment did not eliminate the parasite from immunocompromised hosts. Hence, the purpose of this study was to test whether uninterrupted treatment targeting B. microti PI4K could eradicate B. microti infection in immunocompromised hosts.

Materials and methods

Chemical reagents

MMV390048, sesame oil (SO), atovaquone (ATO), and azithromycin (AZI) were purchased from Sigma-Aldrich (Tokyo, Japan). MMV390048, ATO, and AZI were dissolved in SO to prepare a stock solution with a concentration of 40 mg/ml and kept at 4°C before use. KOD FX Neo DNA polymerase was purchased from Toyobo (Tokyo, Japan). The Big Dye Terminator v3.1 cycle sequencing kit was purchased from Applied Biosystems (Tokyo, Japan).

Parasites and mice

Babesia microti Peabody mjr strain (ATCC® PRA-99™) was purchased from ATCC and stocked in our laboratory. For the maintenance of B. microti, cryopreserved parasitized RBCs were passaged by intraperitoneal (i.p.) injection in donor mice. Six-week-old female severe combined immunodeficiency (SCID) mice and BALB/c mice were purchased from CLEA Japan (Tokyo, Japan) and used for in vivo studies.

Mouse infection and drug administration

To confirm the efficacy of uninterrupted treatment targeting PI4K, 15 SCID mice were randomly divided equally into 3 groups and intraperitoneally injected with $1 \times 10^7$ B. microti. Blood smears were prepared every other day, and the hematocrit (HCT) was measured every four days. Treatment was initiated at 4 days post-infection (DPI) when mouse parasitemia is ~1%. This timeline was followed since early clinical manifestations are observed when parasitemia exceeds 1% in babesiosis patients (Akel and Mobarakai, 2017). Daily treatment with 20 mg/kg MMV390048, 20 mg/kg ATO plus 20 mg/kg AZI, and 0.2 ml vehicle (sesame oil) was given orally to each group, respectively (Bathiha et al., 2020; Tuvshintulga et al., 2022). These treatments were discontinued when mice tested negative by PCR detection of B. microti 18S ribosomal RNA (18S-rRNA) gene. To isolate the B. microti Cytb mutant strain, parasites from the SCID mouse treated with ATO plus AZI were collected and passaged in a donor SCID mouse. To evaluate the efficacy of PI4K inhibitor on ATO-resistant parasites, 15 BALB/c mice were randomly divided equally into 3 groups and intraperitoneally injected with $1 \times 10^7$ B. microti Cytb mutant strain. A 7-day treatment was given to mouse groups as described above and the parasitemia and HCT levels were monitored.
Detection of *B. microti* 18S-rRNA gene and surveillance of gene variants

Blood samples were collected from the tail vein and were diluted in PBS, followed by incubation at 100°C for 5 min. After incubation, the samples were centrifuged at 10,000 rpm for 5 min and the supernatants were collected and used for detection. To rule out false negative results, the samples were checked using Qubit™ 1× dsDNA BR assay kit (Thermo Fisher Scientific) and Qubit® 2.0 fluorometer (Thermo Fisher Scientific) before running the PCR assay to ensure that genomic DNA was present. Detection of the 18S-rRNA gene started 16 DPI and was used to evaluate whether the parasites were cleared from the SCID mice. Gene amplification was performed following a previously described protocol (Persing et al., 1992). The Cytb and rpl4 mutations were determined by Sanger sequencing (Tuvshintulga et al., 2022). The obtained sequence was aligned with the wild type sequence. A genetic variant was detected in Cytb gene and deposited in GenBank database with accession no. ON815034.

Statistical analysis

The differences in parasitemia and HCT between control and treated groups were analyzed using the one-way analysis of variance using GraphPad Prism (La Jolla, CA, USA). A P value of < 0.05 was considered to be statistically significant.

Results

Radical cure of human babesiosis by uninterrupted treatment targeting phosphatidylinositol 4-kinase

Treatment with MMV390048 showed potent efficacy against *B. microti*, evidenced by abated parasitemia from 5 DPI and undetectable parasites in blood smears from 8 DPI (Figure 1A). Moreover, parasites were no longer detectable by PCR from 64 DPI to 92 DPI (Figure 2). At 10 DPI, parasites in the vehicle-treated group reached the highest parasitemia (average 60.6%), with a transient and slight decline at 14 DPI, and maintained

![Graph showing parasitemia and HCT changes over time](image)
fluctuating parasitemia until the end of the trial. The mean parasitemia significantly differed between the vehicle-treated and MMV390048-treated groups from 6 DPI (Figure 1A). In ATO plus AZI-treated group, parasites were initially inhibited until 22 DPI, but the parasitemia rapidly increased from 24 DPI and reached its peak at 32 DPI (average 40.1%) (Figure 1A). From 30 DPI, the ATO plus AZI was ineffective on parasite growth as no significant difference in parasitemia was observed when compared to the vehicle-treated group. In addition, markedly lower HCT levels were recorded in vehicle-treated and ATO plus AZI-treated groups from 8 DPI and 32 DPI, respectively (Figure 1B). The Cytb and rpl4 genes were sequenced from relapsed parasites and a single nucleotide variant (SNV) of the Cytb gene was detected as a non-synonymous coding change at position 272 (Y272C) (Figure 3). Meanwhile, there was no mutation detected in the rpl4 gene.

Inhibitory efficacy of MMV390048 against ATO-resistant B. microti strain

The next step was to evaluate the sensitivity of B. microti Cytb mutant strain to MMV390048. In the vehicle-treated group, B. microti Cytb mutant strain rapidly increased in mice and reached peak parasitemia at 10 DPI (average 36.7%) and a lower HCT level was observed from 12 DPI (Figure 4). As expected, ATO plus AZI was ineffective against the B. microti Cytb mutant strain (Figure 4A). No significant difference in the level of parasitemia was observed between vehicle- and ATO plus AZI-treated groups. In contrast, the growth of B. microti Cytb mutant strain and the development of anemia were significantly inhibited upon treating mice with MMV390048 (Figure 4B).

Discussion

To avoid developing drug resistance, the treatment for human babesiosis usually consists of a two-drug combination, such as ATO plus AZI (Krause et al., 2000). Despite this, acquired drug resistance is well documented in some severe cases in immunocompromised patients (Krause et al., 2008; Wormser et al., 2010; Vannier and Krause, 2012; Simon et al., 2017). Hence, the radical cure of babesiosis remains challenging in severely immunocompromised patients. In the recent past, a few compounds have been reported as promising drugs against human babesiosis, namely endochin-like quinolones (ELQs) (Lawres et al., 2016; Chiu et al., 2021), tafenoquine (Mordue and Wormser, 2019; Liu et al., 2021), and clofazimine (Tuvshintulga et al., 2022). ELQs showed inhibitory effects against apicomplexan parasites by targeting Cytb (Doggett et al., 2012; Stickles et al., 2015). In babesiosis, a 7-day treatment of

FIGURE 2
Molecular detection of parasite DNA in the blood of MMV390048-treated group (#1-5) at 92 DPI. The red arrow shows the expected band length of 154 bp for the B. microti 18S-rRNA gene.
ELQ-334 plus ATO prevented the recrudescence in the SCID mouse model of *B. microti* infection (Lawres et al., 2016). Similarly, a 10-day treatment of ELQ-502 monotherapy or in combination with ATO resulted in the radical cure of babesiosis with no recrudescence in the mouse model (Chiu et al., 2021). Tafenoquine was approved by U. S. Food and Drug Administration (FDA) in 2018 for the radical cure of *Plasmodium vivax* infection and chemoprophylaxis of malaria.
In SCID mice, tafenoquine showed strong inhibition against *B. microti* infection, evident from the single dose requirement (Mordue and Wormser, 2019; Liu et al., 2021). Tafenoquine treatment in cases of relapsing babesiosis caused by drug-resistant *B. microti* is followed by resolution of parasitemia and symptoms in the patient, demonstrating tafenoquine’s excellent effectiveness in clinical settings (Marcos et al., 2022; Rogers et al., 2022). However, the use of tafenoquine entails the risk of inducing severe hemolytic anemia in G6PD-deficient patients (Peters and Van Noorden, 2009).

Clofazimine combined with ATO was also evaluated as a candidate for human babesiosis. Uninterrupted treatment of clofazimine with ATO resulted in the radical cure of *B. microti* in 44 days (Tuvshintulga et al., 2022). Phosphatidylinositol kinases (PIKs) are essential in the regulation of cell proliferation, survival, and membrane trafficking (Hassett and Roepe, 2018). Currently, six *P. falciparum* genes are hypothesized to encode PIKs, while in *Babesia* species, these genes are still unidentified (Hassett and Roepe, 2018). In *Plasmodium*, PI4K phosphorylates lipids to regulate intracellular signaling and trafficking, making it a druggable target to eliminate malaria (McNamara et al., 2013). In blood stages, the inhibitor prevents the parasite’s development by disrupting plasma membrane ingestion around the developing daughter merozoites. *B. microti* PI4K shares an identity value of 62.8% with *P. falciparum* and is highly conserved among *Babesia* species (Ji et al., 2022). Hence, we speculate that the mechanism in *Plasmodium* also applies to *Babesia* species. MMV390048 is an inhibitor of *Plasmodium* PI4K which was under evaluation in human clinical trials (Sinxadi et al., 2020). A previous study reported MMV390048 has potent inhibition against *Babesia* species by targeting PI4K, revealing a promising druggable target (Ji et al., 2022). In light of this, we further examined if targeting PI4K by monotherapy is sufficient to achieve the radical cure of *B. microti* infection in SCID mice. In this study, we used MMV390048 as an inhibitor for *B. microti* PI4K (*Bm*PI4K) and a 64-day uninterrupted treatment with MMV390048 succeeded in curing babesiosis in *B. microti*-infected SCID mice. This finding suggests that targeting PI4K in *Babesia* species may be a viable therapeutic strategy.
infected SCID mice. Although this therapy was longer than in ELQ-502 (10 days) and clofazimine with ATO (44 days), we have confirmed that PI4K is a promising target for the clearance of parasites. Meanwhile, in ATO plus AZI-treatment group, the parasite established resistance to ATO and AZI, in addition to the development of a single amino acid mutation (Y272C) in the B. microti Cytb gene. Y272 is highly conserved among apicomplexan parasites and the site mutation of Y272 will confer a high degree of resistance to the drug (Fisher and Meunier, 2008; Lemieux et al., 2016). Moreover, B. microti Y272C mutation has been described in a clinical case and caused treatment failure (Simon et al., 2017). MMV390048 also demonstrated potent inhibition of B. microti Cytb mutant strain. Despite MMV390048 exhibiting a good inhibitory effect, Babesia tends to be more tolerant than Plasmodium when treated with MMV390048. Hence, if MMV390048 were to be used for treating human babesiosis, the recommended dose should be higher than 120 mg (a safety dose test in human clinical trials) (Sinzadi et al., 2020; Ji et al., 2022). Moreover, the accompanying safety issues should be considered and future work can focus on developing and designing Babesia PI4K-specific inhibitors, as well as the development of MMV390048-combined therapeutics. This will accelerate the development of next-generation anti-babesiosis therapeutics to eliminate Babesia infection. In summary, results from the present study revealed that targeting BmPI4K not only suppresses parasite growth but also eradicates parasites in immunocompromised hosts, especially in relapsing infections caused by ATO-resistant B. microti strain.

Conclusion

Based on the preceding findings, we conclude that BmPI4K is a feasible and promising drug target for the elimination of B. microti infection. This study opens new avenues to rationally design inhibitors with improved drug-like properties against Babesia species.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/nuccore/ON815034.

References

Akel, T., and Moharakai, N. (2017). Hematologic manifestations of babesiosis. Ann. Clin. Microbiol. Antimicrob. 16, 6. doi:10.1186/s12941-017-0179-z

Bathia, G. E., Beechiby, A. M., Alkaizu, L. M., Nadwa, E. H., Rashwan, E. K., Yokoyama, N., et al. (2020). In vitro and in vivo growth inhibitory activities of cryptolepine hydrate against several babesia species and theileria equi. PLoS Negl. Trop. Dis. 14, e0008489. doi:10.1371/journal.pntd.0008489

Chiu, J. E., Renard, J., Pal, A. C., Singh, P., Vydyan, P., Thkkiniath, J., et al. (2021). Effective therapy targeting cytochrome bcl prevents babesia erythrocytic...
development and protects from lethal infection. *Antimicrob. Agents Chemother.* 65, e00622-21. doi: 10.1128/AAC.00622-21

Doughter, J. S., Nilsson, A., Forquer, J., Wegmann, K. W., Jones-Brando, L., Yolken, R. H., et al. (2012). Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. *Proc. Natl. Acad. Sci. U. S. A.* 109, 15936–15941. doi: 10.1073/pnas.1208069109

Fisher, N., and Menunier, B. (2008). Molecular basis of resistance to cytochrome bc1 inhibitors. *FEBS Yeast Res.* 8, 183–192. doi: 10.1111/j.1567-1364.2007.00328.x

Hassett, M. R., and Roepe, P. D. (2018). PIK-ing new malaria chemotherapy. *Trends Parasitol.* 34, 925–927. doi: 10.1016/j.pt.2018.06.003

Ji, S., Galon, E. M., Rizk, M. A., Yi, Y., Zafar, I., Li, H., et al. (2022). Efficacy of the antimalarial MMV390048 against babesia infection reveals phosphatidylinositol 4-kinase as a druggable target for babesiosis. *Antimicrob. Agents Chemother.* 66, e005742-22. doi: 10.1128/ääc.00574-22

Krause, P. J. (2019). Human babesiosis. *Int. J. Parasitol.* 49, 165–174. doi: 10.1016/j.ijpara.2018.11.007

Krause, P. J., Gewurz, B. E., Hill, D., Marty, F. M., Vannier, E., Foppa, I. M., et al. (2008). Persistent and relapsing babesiosis in immunocompromised patients. *Clin. Infect. Dis.* 46, 370–376. doi: 10.1086/525852

Krause, P. J., Lepore, T., Sikand, V. K., Gadhab, J. Jr., Burke, G., Telford, S. R. 3rd., et al. (2000). Atovaquone and azithromycin for the treatment of babesiosis. *N. Engl. J. Med.* 343, 1454–1458. doi: 10.1056/NEJM200011163432004

Lawrence, L. A., Garg, A., Kumar, V., Bruzual, I., Forquer, I. P., Renard, L. et al. (2016). Radical cure of experimental babesiosis in immunodeficient mice, using a combination of an endochin-like quinolone and atovaquone. *J. Exp. Med.* 213, 1307–1318. doi: 10.1084/jem.20151519

Lemieux, J. E., Tran, A. D., Freemark, L., Schaffner, S. F., Goethert, H., Andersen, K. G., et al. (2016). A global map of genetic diversity in babesia microti reveals strong population structure and identifies variants associated with clinical relapse. *Nat. Microbiol.* 1, 16079. doi: 10.1038/nmicrobiol.2016.79

Li, Y. P., Mehrabi, R., Hu, Y. F., Faran Ashraf Baig, M. M., Abbas, M., Akhtar, F., et al. (2021). Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases. *Eur. J. Pharmacol.* 907, 174300. doi: 10.1016/j.ejphar.2021.174300

Liu, M., Ji, S., Kondoh, D., Galon, E. M., Li, J., Tomihari, M., et al. (2021). Tafenoquine is a promising drug candidate for the treatment of babesiosis. *Antimicrob. Agents Chemother.* 65, e02042-21. doi: 10.1128/AAC.02042-21

Marcos, L. A., Leung, A., Kirkman, L., and Wormser, G. P. (2022). Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone. *IDCases.* 27, e01460. doi: 10.1016/j.jidcases.2022.e01460

McNamara, C. W., Lee, M. C., Lim, C. S., Lim, S. H., Roland, J., Simon, O., et al. (2013). Targeting plasmodium PI (4)K to eliminate malaria. *Nature.* 504, 248–253. doi: 10.1038/nature12782

Mordue, D. G., and Wormser, G. P. (2019). Could the drug tafenoquine revolutionize treatment of babesia microti infection? *J. Infect. Dis.* 220, 442–447. doi: 10.1093/infdis/jiz119

Paquet, T., Le Manach, C., Cabrera, D. G., Younis, Y., Henrich, P. P., Abraham, T. S., et al. (2017). Antimalarial efficacy of MMV390048, an inhibitor of plasmodium phosphatidylinositol 4-kinase. *Sci. Transl. Med.* 9, eaa4735. doi: 10.1126/scitranslmed.aad9735

Persing, D. H., Mathiesen, D., Marshall, W. F., Telford, S. R., Spielman, A., Thomford, J. W., et al. (1992). Detection of babesia microti by polymerase chain reaction. *J. Clin. Microbiol.* 30, 2097–2103. doi: 10.1128/jcm.30.8.2097-2103.1992

Peters, A. L., and Van Noorden, C. J. (2009). Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. *J. Histochim Cytochem* 57, 1083–1011. doi: 10.1176/jhc.2009-053828

Renard, I., and Ben Mamoun, C. (2021). Treatment of human babesiosis: Then and now. *Pathogens.* 10, 1120. doi: 10.3390/pathogens10091210

Rogers, K., Krause, P. J., Norris, A. M., Ting, M. H., Nagami, E. H., Colley, B., et al. (2022). Broad antimicrobial resistance in a case of relapsing babesiosis successfully treated with tafenoquine. *Clin. Infect. Dis.* 10, cia6737. doi: 10.1093/cid/cia6737

Simon, M. S., Westblade, L. F., Driedzich, A., Visoné, J. E., Furman, R. R., Jenkins, S. G., et al. (2017). Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed babesia microti infection associated with retuximab and chronic lymphocytic leukemia. *Clin. Infect. Dis.* 65, 1222–1225. doi: 10.1093/cid/cia677

Sinnadurai, P., Donini, C., Johnstone, H., Langdon, G., Wiesner, L., Allen, E., et al. (2020). Safety, tolerability, pharmacokinetics, and antimalarial activity of the novel plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048 in healthy volunteers. *Antimicrob. Agents Chemother.* 64, e01896-e01819. doi: 10.1128/AAC.01896-19

Stickles, A. M., de Almeida, M. J., Morrissey, J. M., Sheridan, K. A., Forquer, I. P., Nilsen, A. et al. (2015). Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of plasmodium falciparum. *Antimicrob. Agents Chemother.* 59, 1977–1982. doi: 10.1128/AAC.04149-14

Tuvshintulga, B., Sivakumar, T., Nugraha, A. B., Ahedor, B., Batmagnai, E., Otsgonsuren, D., et al. (2022). Combination of clofazimine and atovaquone as a potent therapeutic regimen for the radical cure of babesia microti infection in immunocompromised hosts. *J. Infect. Dis.* 223, 238–242. doi: 10.1093/infdis/jiab537

Vannier, E. G., Diuk-Wasser, M. A., Ben Mamoun, C., and Krause, P. J. (2015). Babesiosi. *Infect. Dis. Clin. North Am.* 29, 357–370. doi: 10.1016/j.idc.2015.02.008

Vannier, E., and Krause, P. J. (2012). Human babesiosis. *N Engl. J. Med.* 366, 2397–2407. doi: 10.1056/NEJMra1202188

Watson, J. A., Nekkid, N., and White, M. (2021). Tafenoquine for the prevention of plasmodium vivax malaria relapse. *Lancet Microbe.* 2, e175–e176. doi: 10.1016/S2666-5247(21)00062-8

Wormser, G. P., Prasad, A., Neuhaus, E., Joshi, S., Nowakowski, J., Nelson, J., et al. (2010). Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with babesia microti infection. *Clin. Infect. Dis.* 50, 381–386. doi: 10.1086/649859